Format

Send to

Choose Destination
See comment in PubMed Commons below
Rheumatology (Oxford). 2013 May;52(5):888-92. doi: 10.1093/rheumatology/kes386. Epub 2013 Jan 7.

Methotrexate for pain relief in knee osteoarthritis: an open-label study.

Author information

1
Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, UK.

Abstract

OBJECTIVE:

Synovitis is very common in knee OA and associated with pain. This open-label study evaluated an anti-synovitis therapy, MTX, for pain relief in knee OA.

METHODS:

Inclusion criteria included pain visual analogue scale (VAS) >40/100 mm, ACR clinical criteria for knee OA and intolerance/inefficacy of NSAID and opioids. US at baseline and 24 weeks assessed effusion and synovial thickness. Patients received MTX up to 20 mg/week for 24 weeks.

RESULTS:

Thirty participants were recruited; mean age 64.5 years, median pain VAS 68 mm. At 24 weeks, 13/30 (43%) achieved ≥30% reduction in pain VAS, 7 (23%) achieved ≥50% reduction and 4 (13%) had worsened. Thirteen achieved Osteoarthritis Research Society International (OARSI) responder criteria. All had effusion/synovitis at baseline. There was no correlation between change in imaging and change in pain scores at 24 weeks.

CONCLUSION:

This open-label trial suggests analgesic efficacy for MTX in OA knee and suggests that a randomized controlled trial is warranted. Trial Registration. Current controlled trials, http://www.controlled-trials.com/, ISRCTN66676866.

PMID:
23300331
DOI:
10.1093/rheumatology/kes386
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center